Results 1 to 10 of about 28,652 (194)
Rivaroxaban and Hemostasis in Emergency Care [PDF]
Emergency Medicine International, 2014 Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban
Jürgen Koscielny, Edita Rutkauskaite
doaj +4 more sources
Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran [PDF]
BMC Health Services ResearchBackground Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD).
Zahra Goudarzi +5 more
doaj +2 more sources
In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments [PDF]
Frontiers in PharmacologyBackgroundApixaban (API) and rivaroxaban (RIVA) are orally available inhibitors of coagulation factor Xa and are commonly used to treat cancer-related venous thrombosis.
Zihan Liu +9 more
doaj +2 more sources
Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients [PDF]
Clinical and Applied Thrombosis/HemostasisRivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH ...
Kaitlin Blotske PharmD +7 more
doaj +2 more sources
Rivaroxaban in COMPASS trial [PDF]
Vnitřní lékařství, 2020 Cardiovascular diseases (CVD) are still at the first place in the case of mortality in European countries. Consistent secondary prevention for CVD is very important aspect in the fight with this negative statistics. We consider antithrombotic treatment as a gold standard in secondary prevention for CVD .
Miroslav Souček, Filip Šustr
openaire +3 more sources
Frontiers in Pharmacology, 2021 Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion.
Rui-juan Xu +5 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Peritoneovenous shunts (PVSs) are used to relieve ascites in cirrhosis. Disseminated intervascular coagulation (DIC) is a complication of PVSs requiring immediate PVS removal.
Fabienne Lucas +4 more
doaj +1 more source
Clinical medicine. Blood disorders, 2010 Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need for regular monitoring and frequent dose adjustment ...
Osama M Moussa +2 more
openaire +4 more sources
Research and Practice in Thrombosis and Haemostasis, 2021 Background Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. Objectives To demonstrate and compare menstrual patterns and actions taken
Kochawan Boonyawat +9 more
doaj +1 more source
Clinical and Translational Science, 2022 Rivaroxaban is an oral anticoagulant that inhibits thrombin and blocks coagulation cascade through directly inactivating factors Xa. Despite rivaroxaban is widely used for prevention and treatment of venous thrombosis, and its common adverse reactions ...
Ming Zhao +8 more
doaj +1 more source